

# Aurelie Philippe

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7788846/publications.pdf>

Version: 2024-02-01

29  
papers

1,339  
citations

471509

17  
h-index

501196

28  
g-index

29  
all docs

29  
docs citations

29  
times ranked

1684  
citing authors

#	ARTICLE	IF	CITATIONS
1	Non-HLA antibodies targeting angiotensin II Type 1 receptor and endothelin-1 Type A receptors induce endothelial injury via $\beta$ 2-arrestin link to mTOR pathway. <i>Kidney International</i> , 2022, 101, 498-509.	5.2	14
2	Molecular Effects of Auto-Antibodies on Angiotensin II Type 1 Receptor Signaling and Cell Proliferation. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3984.	4.1	5
3	Autoantibodies Targeting AT1- and ETA-Receptors Link Endothelial Proliferation and Coagulation via Ets-1 Transcription Factor. <i>International Journal of Molecular Sciences</i> , 2022, 23, 244.	4.1	8
4	Angiotensin and Endothelin Receptor Structures With Implications for Signaling Regulation and Pharmacological Targeting. <i>Frontiers in Endocrinology</i> , 2022, 13, 880002.	3.5	7
5	Non-HLA Autoantibodies at 1 Year Negatively Affect 5-Year Native Renal Function in Liver Transplant Recipients. <i>Transplantation Proceedings</i> , 2021, 53, 1019-1024.	0.6	5
6	Autoantibodies to Vasoregulative G-Protein-Coupled Receptors Correlate with Symptom Severity, Autonomic Dysfunction and Disability in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. <i>Journal of Clinical Medicine</i> , 2021, 10, 3675.	2.4	38
7	The emerging field of non-human leukocyte antigen antibodies in transplant medicine and beyond. <i>Kidney International</i> , 2021, 100, 787-798.	5.2	23
8	Unraveling the Prevalence of Angiotensin II Type 1 Receptor Antibodies in Hypertension. <i>American Journal of Hypertension</i> , 2020, 33, 711-712.	2.0	0
9	Diverse Responses of Autoantibodies to the Angiotensin II Type 1 Receptor in Primary Aldosteronism. <i>Hypertension</i> , 2019, 74, 784-792.	2.7	17
10	Angiotensin II Type 1 Receptor Antibodies Trigger Inflammation in Renal Transplantation. <i>Kidney International Reports</i> , 2019, 4, 510-512.	0.8	1
11	Non-HLA agonistic anti-angiotensin II type 1 receptor antibodies induce a distinctive phenotype of antibody-mediated rejection in kidney transplant recipients. <i>Kidney International</i> , 2019, 96, 189-201.	5.2	117
12	Anti-angiotensin II type 1-receptor antibodies (AT1R-Ab) Induce a Specific Phenotype of Rejection Distinct from HLA antibody-Mediated Rejection. <i>Transplantation</i> , 2018, 102, S254.	1.0	1
13	Tempest in a sugar-coated lab vial. <i>American Journal of Transplantation</i> , 2018, 18, 2622-2623.	4.7	1
14	Antibodies against chemokine receptors CXCR3 and CXCR4 predict progressive deterioration of lung function in patients with systemic sclerosis. <i>Arthritis Research and Therapy</i> , 2018, 20, 52.	3.5	44
15	Thy-1+ $\alpha$ 2(I) fibroblast subsets in the human peritoneum. <i>American Journal of Physiology - Renal Physiology</i> , 2017, 313, F1116-F1123.	2.7	6
16	Non-HLA Antibodies Impact on C4d Staining, Stellate Cell Activation and Fibrosis in Liver Allografts. <i>Transplantation</i> , 2017, 101, 2399-2409.	1.0	42
17	Non-HLA antibodies against endothelial targets bridging allo- and autoimmunity. <i>Kidney International</i> , 2016, 90, 280-288.	5.2	92
18	Renal Ischemia/Reperfusion Injury in Soluble Epoxide Hydrolase-Deficient Mice. <i>PLoS ONE</i> , 2016, 11, e0145645.	2.5	22

#	ARTICLE	IF	CITATIONS
19	Pretransplant Sensitization Against Angiotensin II Type 1 Receptor Is a Risk Factor for Acute Rejection and Graft Loss. <i>American Journal of Transplantation</i> , 2013, 13, 2567-2576.	4.7	186
20	The proto-oncogene c-Fos transcriptionally regulates VEGF production during peritoneal inflammation. <i>Kidney International</i> , 2013, 84, 1119-1128.	5.2	51
21	Non-HLA antibodies in solid organ transplantation. <i>Current Opinion in Organ Transplantation</i> , 2013, 18, 430-435.	1.6	80
22	Role of non-HLA antibodies in organ transplantation. <i>Current Opinion in Organ Transplantation</i> , 2012, 17, 440-445.	1.6	47
23	Non-HLA-antibodies targeting Angiotensin type 1 receptor and antibody mediated rejection. <i>Human Immunology</i> , 2012, 73, 1282-1286.	2.4	43
24	Involvement of functional autoantibodies against vascular receptors in systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 530-536.	0.9	254
25	From mother to child-transplacental effect of AT1R-AAin preeclampsia. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 1774-1776.	0.7	3
26	Autoimmune mediated G-protein receptor activation in cardiovascular and renal pathologies. <i>Thrombosis and Haemostasis</i> , 2009, 101, 643-648.	3.4	49
27	Autoimmune mediated G-protein receptor activation in cardiovascular and renal pathologies. <i>Thrombosis and Haemostasis</i> , 2009, 101, 643-8.	3.4	23
28	Nephrin Mutations Can Cause Childhood-Onset Steroid-Resistant Nephrotic Syndrome. <i>Journal of the American Society of Nephrology: JASN</i> , 2008, 19, 1871-1878.	6.1	119
29	A missense mutation in podocin leads to early and severe renal disease in mice. <i>Kidney International</i> , 2008, 73, 1038-1047.	5.2	41